RAS is one of the most frequently mutated genes in human cancers, present in about 20 percent of all cases. Its protein product acts as a master regulator of cell proliferation by initiating multiple downstream signalling cascades. Oncogenic mutations lock RAS protein in an active, GTP-bound state, relentlessly promoting cell division and tumorigenesis. Despite being a key cancer driver, directly targeting RAS has long eluded drug developers due to its high affinity for GTP/GDP and the smooth surfaces devoid of good binding pockets.

Instead, the research teams focused on a critical effector of RAS: the phosphoinositide 3-kinase enzyme PI3K, which propagates signals essential for cell growth and survival. However, indiscriminate inhibition of PI3K has posed significant clinical challenges because this enzyme also participates in vital functions like insulin signalling. Inhibitors that block PI3K broadly often incur metabolic toxicities such as hyperglycemia, limiting their therapeutic window.

To solve this conundrum, scientists employed a combination of sophisticated chemical biology methods and selective compound screening to identify molecules capable of covalently binding near the RAS-binding domain of PI3Kα isoform. These small molecules irreversibly attach to specific amino acid residues at the PI3K surface, effectively occluding the RAS binding site. Remarkably, this selectivity preserves PI3K’s ability to engage with other interaction partners, such as those in the insulin signalling axis, thereby reducing systemic side effects.

A bespoke biochemical assay developed at the Crick Institute enabled the verification that these covalent inhibitors disrupted the PI3K-RAS interaction with high specificity. Structural and functional characterizations confirmed that the compounds prevent the pathogenic activation loop driven by mutant RAS without compromising normal enzyme activity necessary for homeostasis. This targeted mechanism represents a major leap forward in precision oncology.

The in vivo efficacy of one leading compound was judiciously evaluated in mouse models engineered to develop RAS-mutated lung tumors. Treatment led to significant arrest of tumor progression without detectable increases in blood glucose levels. This outcome underscores the concept that uncoupling RAS-dependent oncogenic signalling from PI3K can suppress tumors effectively while sparing healthy physiology, a milestone in mitigating the therapy-limiting toxicities observed with previous PI3K inhibitors.

Further investigations demonstrated that combining the PI3K-RAS interaction blocker with other drugs targeting parallel nodes within the RAS pathway resulted in synergistic and durable tumor control. The combination therapies enhanced suppression of tumor growth beyond the capability of single agents, providing a compelling rationale for multi-modal treatment regimens leveraging pathway redundancies to overcome cancer resistance mechanisms.

The scope of the drug’s utility expanded unexpectedly when researchers explored its effects against HER2-driven tumors, commonly found in breast cancer and characterized by overexpression of the HER2 receptor tyrosine kinase. Since HER2 also signals via PI3K, but operates independently of RAS, the inhibitor nonetheless blocked PI3K-driven tumor growth in these models. This intriguing discovery implies the drugs could serve as versatile therapeutics across a wider spectrum of cancers harboring mutations in either RAS or HER2 oncogenes.

Following these promising preclinical results, the lead compound has entered Phase 1 clinical trials designed to assess safety, tolerability, and preliminary efficacy in patients with tumors driven by RAS or HER2 mutations. The trial will also investigate whether administering the drug in combination with other agents targeting RAS-associated pathways enhances therapeutic outcomes. The initiation of this clinical evaluation represents a significant translational achievement stemming from deep mechanistic insights into protein-protein interactions and covalent drug design.

Julian Downward, Principal Group Leader at the Francis Crick Institute, highlighted the perseverance required to address one of oncology’s most challenging targets: “Our journey to disrupt RAS-driven signalling without harmful side effects reflects decades of fundamental biology research and innovative chemistry. The ability to selectively prevent RAS from binding PI3K while preserving other cellular functions exemplifies how nuanced targeting can unlock new treatment avenues.”

Matt Patricelli, Chief Scientific Officer at Vividion Therapeutics, emphasized the transformative potential of this discovery for drug development: “These covalent inhibitors open a fresh paradigm for targeting oncogenic signalling complexes. By precisely blocking pathological protein interactions rather than entire enzymes, we have created molecules that can thwart tumor growth while maintaining normal cellular processes. Seeing this science advance into the clinic is truly rewarding.”

This breakthrough exemplifies the power of combining chemical biology, structural insights, and rigorous preclinical validation to overcome long-standing barriers in drug discovery. Should clinical trials validate safety and efficacy in humans, these compounds offer hope for improved therapies that can more effectively combat cancers driven by RAS and HER2 mutations without the burden of debilitating side effects. The approach also lays the groundwork for the design of next-generation molecular glues and inhibitors that selectively modulate oncogenic signalling pathways with unprecedented precision.

The Francis Crick Institute continues its mission to translate fundamental scientific insights into impactful medical advances that can save and improve lives. This collaboration with Vividion Therapeutics underscores the synergy between academic research and industry innovation, fostering rapid development of targeted cancer therapies. As this drug candidate progresses through clinical evaluation, it positions itself at the forefront of precision oncology focused on exploiting vulnerabilities in cancer cell signalling networks.

Subject of Research: Targeted disruption of the RAS-PI3K interaction to inhibit tumor growth in cancers driven by RAS and HER2 mutations.

Article Title: Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2

News Publication Date: 9 October 2025

Web References: http://dx.doi.org/10.1126/science.adv2684

References: Klebba, J. et al. (2025). Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2. Science. 10.1126/science.adv2684.

Keywords: Drug discovery, Tumor cells

Inflammatory skin diseases such as psoriasis, atopic dermatitis, and lupus-related cutaneous manifestations present a multifaceted clinical challenge due to their complex pathogeneses involving aberrant immune signaling pathways. Current treatments often rely on broad-spectrum immunosuppression, which can compromise systemic immunity and induce significant side effects. Addressing these limitations, the researchers focused on harnessing selective immune checkpoint modulation, targeting CD200R—an inhibitory receptor expressed primarily on myeloid cells and certain lymphocyte subsets, known to regulate immune homeostasis and inflammatory processes.

Ucenprubart is engineered as an agonistic monoclonal antibody that selectively binds to CD200R, triggering downstream signaling that attenuates pro-inflammatory cytokine production and immune cell activation. Unlike antagonistic antibodies that block receptor activity, Ucenprubart mimics the natural ligand, CD200, thereby promoting immune tolerance and resolution of inflammation in affected tissue microenvironments. This targeted mechanism offers high specificity with potentially fewer off-target effects compared to conventional immunosuppressants.

Preclinical development involved a rigorous battery of in vitro and in vivo experiments to evaluate the pharmacodynamics, pharmacokinetics, and safety profile of Ucenprubart. Cellular assays in human peripheral blood mononuclear cells demonstrated potent suppression of inflammatory cytokines such as TNF-alpha, IL-6, and IL-17 upon antibody treatment, confirming its functional engagement with CD200R. Moreover, murine models of psoriasiform dermatitis and contact hypersensitivity exhibited significant clinical improvement and histopathological reduction of immune infiltration after systemic administration of Ucenprubart.

Toxicology studies further reinforced its favorable safety margins, revealing minimal immunogenicity and no evidence of organ toxicity, even at supra-therapeutic doses. Notably, Ucenprubart’s biophysical properties were optimized to enhance receptor binding affinity and in vivo stability, critical parameters enhancing its therapeutic potential. These preclinical data provided a strong rationale to advance into human clinical trials.

The Phase 1 clinical study was designed as a randomized, double-blind, placebo-controlled, dose-escalation trial conducted in healthy volunteers and individuals with mild-to-moderate inflammatory skin disease. Primary endpoints focused on the assessment of safety, tolerability, and pharmacokinetics, while secondary endpoints explored preliminary efficacy signals through biomarker analyses and clinical scoring systems such as EASI (Eczema Area and Severity Index).

Encouragingly, Ucenprubart was well tolerated across all dose cohorts with no serious adverse events reported. Pharmacokinetic profiling revealed a half-life consistent with monoclonal antibody therapeutics, supporting convenient dosing schedules. Biomarker studies aligned with the proposed mechanism of action showed a dose-dependent increase in anti-inflammatory cytokine levels and a concomitant reduction in markers of immune activation. Although the study was not powered to assess efficacy definitively, several participants exhibited measurable improvement in skin lesion severity and pruritus intensity.

The success of Ucenprubart represents the first clinical translation of CD200R agonism as a therapeutic strategy. This paradigm shift emphasizes immune regulation rather than suppression, potentially minimizing infection risks that plague many immune-targeting therapies. Furthermore, the modular design of Ucenprubart opens avenues toward combination regimens with existing biologics or small molecules, aiming for synergistic control over multifactorial inflammatory pathways.

Mechanistically, the CD200-CD200R axis functions as a critical checkpoint in preventing excessive immune activation by delivering inhibitory signals that curtail myeloid cell-mediated inflammation. Dysregulation of this pathway has been implicated in chronic inflammatory conditions and autoimmunity, underscoring the therapeutic rationale for its modulation. By leveraging an agonistic antibody, Ucenprubart effectively restores this natural regulatory circuit, promoting tissue homeostasis and limiting pathological immune responses.

The broader implications of this study extend beyond dermatology. Given the ubiquitous expression of CD200R in various immune compartments, analogous approaches may be applied to other inflammatory and autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Ongoing studies are already investigating these possibilities, spurred by the robust safety and mechanistic data emerging from the skin disease trials.

From a pharmaceutical development perspective, the engineering of Ucenprubart encompassed advanced antibody humanization, affinity maturation, and Fc domain optimization. These molecular modifications enhance its clinical utility by reducing immunogenicity, improving receptor specificity, and modulating effector functions to prevent undesired immune activation like antibody-dependent cellular cytotoxicity (ADCC). Such precision engineering exemplifies the new generation of biologics tailored for maximum efficacy and safety.

The clinical research pathway for Ucenprubart will now advance into Phase 2 trials, designed to evaluate efficacy in larger cohorts and diverse patient populations, including those with moderate to severe disease phenotypes refractory to existing therapies. These studies will integrate molecular imaging, transcriptomic profiling, and patient-reported outcomes to fully elucidate therapeutic impact and biomarkers predictive of response.

Moreover, the research team is exploring biomarker-driven patient stratification strategies to identify individuals most likely to benefit from CD200R agonist therapy, thereby enhancing personalized medicine in inflammatory dermatology. The integration of genomic and proteomic data will facilitate this approach, laying the groundwork for precision immune modulation.

Importantly, the societal burden of inflammatory skin diseases is substantial, encompassing physical discomfort, psychological distress, and economic costs associated with chronic management. Therapies like Ucenprubart, which promise targeted, durable control with improved safety profiles, have the potential to transform quality of life for millions affected worldwide.

The advent of Ucenprubart epitomizes the maturation of immune checkpoint modulation beyond oncology, showcasing the versatility of immunotherapy platforms. Its success underscores the value of translational research bridging molecular immunology, antibody engineering, and clinical investigation to tackle longstanding unmet medical needs.

As data from ongoing and future clinical trials become available, the scientific community eagerly anticipates confirmation of Ucenprubart’s therapeutic promise. If successful, this agonistic antibody could herald a new era in the management of immune-mediated inflammatory diseases, representing a major leap forward in therapeutic innovation.

Strong collaboration between academia, industry, and regulatory bodies has been instrumental in realizing the translational trajectory of Ucenprubart. Continued partnerships will be critical to navigate regulatory approvals, manufacturing scale-up, and market access, ensuring timely delivery of this novel treatment to patients.

In conclusion, the development and initial clinical evaluation of Ucenprubart opens an exciting new frontier in inflammatory skin disease therapy. By harnessing the immune checkpoint functions of CD200R through a finely engineered agonistic antibody, researchers have paved the way for safer, more effective, and mechanism-driven treatment modalities. The coming years promise to reveal the full potential of this groundbreaking therapeutic approach.

Subject of Research: Development and clinical evaluation of Ucenprubart, an agonistic antibody targeting CD200R for inflammatory skin disease treatment.

Article Title: Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical study.

Article References:
Koester, A., Witcher, D.R., Lee, M. et al. Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical study. Nat Commun 16, 4082 (2025). https://doi.org/10.1038/s41467-025-59147-w

Image Credits: AI Generated